Bio-Rad Laboratories, Inc.BIO
NYSE • Healthcare
$279.25
P/E
10.00
PEG
—
FCF Yield
—
Rev Growth YoY
+65.0% YoY
Gross Margin
5201.0%
Health Score
6/10
D/E Ratio
0.16
Confidence
LOW
Business Snapshot
Bio-Rad Laboratories is a global manufacturer and supplier of products and systems used in life science research and clinical diagnostics, including instruments, reagents, and software for biological research, drug discovery, and disease detection. The company operates across two principal segments — Life Science and Clinical Diagnostics — and sells to academic institutions, healthcare facilities, and pharmaceutical companies worldwide. Based on the available price and ratio data, Bio-Rad falls into the mid-to-large cap tier of the healthcare sector, though a precise cap classification cannot be confirmed from the available data.
Financial Health
**Score: 6/10** Bio-Rad carries a conservative balance sheet with a debt-to-equity ratio of just 0.16x, indicating very limited financial leverage and modest bankruptcy risk. The current ratio of 5.62x is exceptionally strong, suggesting the company holds more than five times the liquid assets needed to cover near-term liabilities...
Risk Assessment
- **DATA INTEGRITY:** Gross margin of 5,201% and net margin of 2,942% are almost certainly the result of data errors or one-time non-operating gains, not genuine operating performance, making margin-based analysis unreliable. - **FREE CASH FLOW:** FCF is unavailable, preventing any assessment of whether the company is generating or consuming cash from operations — a critical blind spot for valuation. - **TECHNICALS:** A confirmed "death cross" (50-day moving average crossing below the 200-day) is a bearish technical signal, and the MACD is also signalling bearish momentum. - **PRICE POSITIONING:** The current price of $279.25 sits well below the 52-week high of $343.12, representing a drawdown of approximately 19%, with the stock also below both key moving averages. - **DATA COMPLETENESS:** TTM revenue, TTM net income, and earnings growth are all unavailable, limiting the depth of fundamental analysis that can be performed with confidence. ---...